Clinical efficacy of 0.75% ropivacaine vs. 2% lignocaine hydrochloride with adrenaline (1:80,000) in patients undergoing removal of bilateral maxillary third molars: a randomized controlled trial

Aniket Narayan Kakade, Sanjay S. Joshi, Charudatta Shridhar Naik, Bhupendra Vilas Mhatre, Arsalan Ansari

Department of Oral and Maxillofacial Surgery, Terna Dental College, Navi Mumbai, Maharashtra, India

Background: Lignocaine with adrenaline is routinely used as a local anesthetic for dental procedures. Adrenaline was added to increase the duration of anesthesia. However, epinephrine-containing local anesthetic solutions are not recommended in conditions such as advanced cardiovascular diseases and hyperthyroidism. Recently, ropivacaine has gained popularity as a long-acting anesthetic with superior outcomes. The goal of this study was to assess and compare the effectiveness of 0.75% ropivacaine alone and 2% lignocaine with adrenaline (1:80,000) in the removal of bilateral maxillary wisdom teeth using the posterior superior alveolar nerve block technique.

Methods: This was a single-blind, randomized, split-mouth, prospective study assessing 15 systemically sound outpatients who needed bilateral removal of maxillary third molars. We randomly allocated the sides and sequences of ropivacaine and lignocaine with adrenaline administration. We evaluated the efficacy of both anesthetics with regard to the onset of anesthesia, intensity of pain, variation in heart rate, and blood pressure.

Results: The onset of anesthesia was faster with lignocaine (138 s) than with ropivacaine (168 s), with insignificant differences (p = 0.001). There was no need for additional local anesthetics in the ropivacaine group, while in the lignocaine with adrenaline group, 2 (13.3%) patients required additional anesthesia. Adequate intraoperative anesthesia was provided by ropivacaine and lignocaine solutions. No significant difference was observed in the perioperative variation in blood pressure and heart rate.

Conclusion: Ropivacaine (0.75%) is a safe and an adrenaline-free local anesthetic option for posterior superior alveolar nerve block, which provides adequate intraoperative anesthesia and a stable hemodynamic profile for the removal of the maxillary third molar.

Keywords: Analgesia; Anesthesia; Lignocaine; Ropivacaine.

INTRODUCTION

The most frequently performed outpatient procedure in oral and maxillofacial surgery is tooth removal. Intraoperative pain management with local anesthesia is an essential aspect of this treatment. An ideal option for tooth extraction is a local anesthetic that acts for the optimal duration and provides good analgesia with insignificant toxicity [1].

In clinical dentistry, lignocaine is the recommended local anesthetic agent. Lignocaine solution has intrinsic...
vasodilative properties at commercially available concentrations. As a result, a vasoconstrictor is added (usually epinephrine) to ensure the optimal duration of anesthesia required to perform dental surgery. Lignocaine combined with epinephrine has a rapid onset and provides intermediate pulpal and soft tissue anesthesia [2]. However, in conditions such as hyperthyroidism and significant cardiovascular diseases (American Society of Anesthesiologists physical status grade 3–4), epinephrine containing a local anesthetic solution is not recommended [3]. Moreover, the addition of a vasoconstrictor decreases the pH of the solution, making the local anesthetic injections unpleasant for patients [3].

Ropivacaine has recently gained clinical attention. It has a more secure profile and is equipotent compared with bupivacaine [1]. Recently, ropivacaine has been regarded as superior to other long-acting local anesthetic agents [4]. When used at lower concentrations (such as 0.2%, 0.5%, 0.75%), ropivacaine can cause vasoconstriction, precluding the need for the addition of a vasoconstrictor [1,3]. In comparison to ropivacaine alone, the addition of adrenaline to the ropivacaine solution did not increase its efficacy [1]. Ropivacaine can be administered at various concentrations, including 0.5%, 0.75%, and 1% [4,5]. Compared to 0.5% ropivacaine, the 0.75% solution provides clinically sufficient pulpal anesthesia [2]. A recent study comparing 0.5% and 0.75% ropivacaine for inferior alveolar nerve block in lower third molar surgery showed that 0.75% ropivacaine was more efficacious and desirable [5]. A 2% lignocaine hydrochloride with adrenaline (1:80,000) is safe for hemodynamically healthy patients [6]. In addition, 2% lignocaine with 1:80000 adrenaline is a commonly used anesthetic solution in dentistry. Therefore, we aimed to study and compare 0.75% ropivacaine and 2% lignocaine hydrochloride with 1:80,000 adrenaline in patients undergoing removal of bilateral maxillary wisdom teeth.

**METHODS**

1. **Study design and participants:**
   
   This was a single-blind, randomized, split-mouth, prospective study with a crossover design that was approved by the Ethics Committee of our college (IRB No: TDC/IRB-EC/161/2017) and recorded on the Clinical Trials Registry of India (CTRI/2019/06/019653). The spirit checklist [7] was used to design, conduct, and report the study. The study participants were selected from among patients who visited the oral and maxillofacial surgery outpatient clinic of our college from June 2018 to June 2019. After thoroughly explaining the study, all participants read and signed the written informed consent.

2. **Sample size determination:**

   Based on previous research findings [1] and using the G-Power software version 3.0.10 {power: 0.80, alpha error probability: 0.05, and pain score effect size of 1.0}, the sample size was computed. The size of each group was determined to be 14, which was rounded up to 15.

3. **Sample selection:**

   After a detailed case history recording, followed by clinical and radiographic examinations of 85 patients, 15 patients met the inclusion criteria.

   **Inclusion criteria:**
   - Patients who were ready to participate in the study.
   - Healthy patients aged between 20-50 years, requiring the removal of bilateral maxillary third molars.

   **Exclusion criteria:**
   - Patients who were allergic to amide-type local anesthetic agents, had any systemic disease (cardiovascular disease, hypertension, anxious patients, etc.), pregnant and lactating mothers, and those who were mentally challenged or unable to communicate were excluded.

4. **Intervention**

   The extractions were planned on two different appointments with a minimum gap of seven days. An intradermal test dose of the respective local anesthetics was administered to all participants in the forearm on the day of the procedure. During the appointments,
participants were administered a posterior superior alveolar nerve block for the removal of the maxillary wisdom tooth with either 2 ml solution of 0.75% ropivacaine or 2 ml solution of 2% lignocaine hydrochloride with adrenaline (1:80000) on respective sides, as decided by randomization. A palatally greater palatine nerve block was administered. To administer the anesthetic solution, a sterile Luer lock disposable syringe with a 27-gauge needle was used, and tooth removal was performed. The same operator performed the extractions in all patients. The onset of anesthesia was recorded from the time of removal of the needle following administration of the local anesthetic until objective symptoms were noted. The onset of anesthesia was investigated by probing with a Moon probe per minute as long as the probing did not elicit pain stimulation. The need for additional local anesthesia was also recorded. The intensity of pain during extraction was assessed subjectively using the Verbal Rating Scale (0 = no pain, 1 = mild pain, 2 = moderate pain, 3 = severe pain) [8]. A multiparameter monitor was used to track the changes in heart rate and blood pressure 15 min before the anesthesia, 15 min after the anesthesia, and after the completion of the extraction. Following the extraction, the participants were prescribed antibiotics and analgesics. All data were recorded, including the onset of anesthesia, the intensity of pain during the extraction, the need for additional anesthesia, blood pressure on the right brachial artery, and heart rate in a semi-reclined position. The study was performed in accordance with the Declaration of Helsinki and its later amendments.

**Randomization and concealed random allocation:**

The first session’s anesthetic solution was chosen by simple randomization using a random list with the order of 15. The list was created by the author (A: Lignocaine or B: Ropivacaine). The block randomization method was used with a block size of two to decide the tooth extraction side in the first appointment (AB or BA, A: right maxillary third molar, or B: left maxillary third molar). The orders of both lists were written individually on thick papers, and the papers were then stored in a secured paper pouch. Paper pouches were stored in two separate bins. From each bin, the patient selected a paper pouch. Table 1 shows the sequence of drug administration after randomization during each session.

### Table 1. The sequence of the drug administration after the randomisation

| Patient No. | Drug administered and Side on which drug administered during first session | Drug administered and Side on which drug administered during second session |
|-------------|--------------------------------------------------------------------------------|--------------------------------------------------------------------------------|
| 1           | Ropivacaine (left Side)                                                        | Lignocaine with Adrenaline (right Side)                                       |
| 2           | Ropivacaine (right Side)                                                       | Lignocaine with Adrenaline (left Side)                                        |
| 3           | Lignocaine with Adrenaline (right Side)                                        | Ropivacaine (left Side)                                                       |
| 4           | Ropivacaine (right Side)                                                       | Lignocaine with Adrenaline (left Side)                                        |
| 5           | Ropivacaine (left Side)                                                        | Lignocaine with Adrenaline (right Side)                                       |
| 6           | Ropivacaine (left Side)                                                        | Lignocaine with Adrenaline (right Side)                                       |
| 7           | Lignocaine with Adrenaline (right Side)                                        | Ropivacaine (left Side)                                                       |
| 8           | Ropivacaine (right Side)                                                       | Lignocaine with Adrenaline (left Side)                                        |
| 9           | Ropivacaine (right Side)                                                       | Lignocaine with Adrenaline (left Side)                                        |
| 10          | Ropivacaine (left Side)                                                        | Lignocaine with Adrenaline (right Side)                                       |
| 11          | Ropivacaine (right Side)                                                       | Lignocaine with Adrenaline (left Side)                                        |
| 12          | Lignocaine with Adrenaline (left Side)                                         | Ropivacaine (right Side)                                                      |
| 13          | Ropivacaine (right Side)                                                       | Lignocaine with Adrenaline (left Side)                                        |
| 14          | Ropivacaine (right Side)                                                       | Lignocaine with Adrenaline (left Side)                                        |
| 15          | Lignocaine with Adrenaline (right Side)                                        | Ropivacaine (left Side)                                                      |

5. **Blinding**

In our study, only patients were blinded to the type of local anesthetic administered during each appointment session.
Table 2. Demographic data

| Parameter   | Mean   | Standard Deviation | Range       |
|-------------|--------|--------------------|-------------|
| Age (Years) | 33.1333| 8.3910             | 23-49       |
| Weight (kgs)| 64.4666| 8.5177             | 53-82       |
| Height (cm) | 163.733| 7.7687             | 149-180     |
| BMI         | 24.0333| 1.7674             | 20.7-26.6   |

BMI, body mass index.

6. Statistical analysis:

Windows-based ‘MedCalc Statistical Software’ version 19.0.1 (MedCalc Software bvba, Ostend, Belgium; http://www.medcalc.org; 2019) was used for data analysis. Data normality was checked using the Shapiro-Wilk test. The data passed normality for most of the parameters. Hence, parametric tests were used in the analysis. The onset of anesthesia and vital parameters were compared for the difference between the two treatments (ropivacaine and lignocaine/adrenaline) using a paired t-test assuming equal variances. Fischer’s exact test was used to compare the need for local anesthetics in the two groups. All tests were performed using two-sided tests at an alpha of 0.05. Thus, a “P” value of < 0.05 was used to reject the null hypothesis.
Table 3. Mean, median, SD of Ropivacaine group and Lignocaine with Adrenaline group

|                         | Ropivacaine (n=15) | Lignocaine / Adrenaline (n=15) |
|-------------------------|--------------------|--------------------------------|
|                         | Mean   | Median | SD        | Min - Max | Mean   | Median | SD        | Min - Max |
| Onset (sec.)            | 164.67 | 150    | 53.47     | 90 - 250  | 138.67 | 115    | 51.91     | 100 - 250 |
| SBP (pre)               | 112.67 | 113    | 12.77     | 96 - 135  | 115.93 | 114    | 13.17     | 95 - 139  |
| DBP (pre)               | 73.73  | 73     | 11.04     | 59 - 97   | 73.20  | 76     | 7.67      | 60 - 82   |
| SBP (post)              | 117.13 | 120    | 12.18     | 100 - 140 | 120.87 | 119    | 14.16     | 105 - 146 |
| DBP (post)              | 75.00  | 74     | 6.69      | 67 - 93   | 73.07  | 73     | 9.28      | 58 - 91   |
| SBP (end)               | 116.20 | 116    | 13.66     | 96 - 143  | 119.20 | 117    | 14.26     | 100 - 148 |
| DBP (end)               | 73.33  | 73     | 9.93      | 56 - 96   | 71.93  | 72     | 8.98      | 56 - 86   |
| HR (pre)                | 78.93  | 78     | 4.98      | 72 - 89   | 79.73  | 80     | 6.77      | 70 - 98   |
| HR (post)               | 83.40  | 82     | 5.74      | 76 - 95   | 87.53  | 84     | 8.88      | 77 - 106  |
| HR (end)                | 79.40  | 79     | 6.58      | 70 - 88   | 83.67  | 83     | 6.56      | 70 - 96   |

Abbreviations: DBP, diastolic blood pressure; HR, heart rate; Max, maximum; Min, minimum; SBP, systolic blood pressure; SD, standard deviation.

RESULTS

1. Demographic data

After examining 85 patients who visited the oral and maxillofacial surgery outpatient clinic of our college from June 2018 to June 2019, 15 participants (American Society of Anesthesiology [ASA] physical status 1) were enrolled in the study. Table 2 shows the demographic characteristics of the study population. All 15 participants completed the study, of which three were male and 12 were female. Flow diagram (Fig. 1) summarizes the progress of the subjects throughout the study.

2. Study parameters

Table 3 shows the mean onset of anesthesia in seconds, which was 164.67 seconds (SD ± 53.4) in the ropivacaine group and 138.67 seconds (SD ± 51.9) in the lignocaine with adrenaline group. In the ropivacaine group, mean systolic blood pressure (SBP) 15 min before the administration of local anesthetics was 112.67 mmHg (SD ± 12.7), 15 min after the administration of local anesthetics was 117.13 mmHg (SD ± 12.1), and at the end of the procedure was 116.20 mmHg (SD ± 13.6). In the lignocaine with adrenaline group, mean systolic blood pressure 15 min before the administration of local anesthetics was 115.93 mmHg (SD ± 13.1), 15 min after the administration of local anesthetics was 120.87 mmHg (SD ± 14.1), and at the end of the procedure was 119.20 mmHg (± 14.2). In the ropivacaine group, mean diastolic blood pressure (DBP) 15 min before the administration of local anesthetics was 73.73 mmHg (SD ± 11.0), 15 mins after the administration of local anesthetics was 75.00 mmHg (SD ± 6.69) and at the end of the procedure was 73.33 mmHg (SD ± 9.93). In the lignocaine with adrenaline group, mean diastolic blood pressure 15 mins before the administration of local anesthetics was 73.20 mmHg (SD ± 7.67), 15 min after the administration of local anesthetics was 73.07 mmHg (SD ± 9.28), and at the end of the procedure was 71.93 mmHg (SD ± 8.98). In the ropivacaine group, the mean heart rate 15 min before the administration of local anesthetics was 78.93 beats/mins [bpm] (SD ± 4.98), 15 min after the administration of local anesthetics was 83.40 bpm (SD ± 5.74), and at the end of the procedure was 79.40 bpm (SD ± 6.58). In the lignocaine with adrenaline group, the mean heart rate 15 min before the administration of local anesthetics was 79.73 bpm (SD ± 6.77), 15 min after the administration of local anesthetics was 87.53 bpm (SD ± 8.88), and at the end of the procedure was 83.67 bpm (SD ± 6.56).

Table 4 shows that ropivacaine and lignocaine with adrenaline showed no statistical difference in the onset of anesthesia. In addition, SBP, DBP, and heart rate at different periods were not significantly different between both groups.
Table 4. Comparison between the Ropivacaine group and Lignocaine with adrenaline group

|                  | Pair t-test | Difference | 95% C.I. |
|------------------|------------|------------|----------|
|                  | t         | df | p     | Mean |                      |
| SBP (pre)        | -0.690   | 28 | 0.496 | -3.27 | -12.97 to 6.44        |
| DBP (pre)        | 0.154    | 28 | 0.879 | 0.53  | -6.58 to 7.64         |
| SBP (post)       | -0.774   | 28 | 0.445 | -3.73 | -13.61 to 6.15        |
| DBP (post)       | 0.655    | 28 | 0.518 | 1.93  | -4.12 to 7.98         |
| SBP (end)        | -0.588   | 28 | 0.561 | -3.00 | -13.45 to 7.45        |
| DBP (end)        | 0.405    | 28 | 0.688 | 1.40  | -5.68 to 8.48         |
| HR (pre)         | -0.369   | 28 | 0.715 | -0.80 | -5.24 to 3.64         |
| HR (post)        | -1.514   | 28 | 0.141 | -4.13 | -9.73 to 1.46         |
| HR (end)         | -1.778   | 28 | 0.086 | -4.27 | -9.18 to 0.65         |

Wilcoxon test

|                  | +ve differences | -ve differences | p    | 95% C.I. |
|------------------|-----------------|-----------------|------|---------|
| Onset (sec.)     | 5               | 10              | 0.1205 | 26.00 | -13.41 to 65.41 |

Abbreviations: CI, confidence interval; DBP, diastolic blood pressure; HR, heart rate; SBP, systolic blood pressure.

Need for additional local anesthetics (Table 5): There was no need for additional local anesthetics in the ropivacaine group, while in the lignocaine with adrenaline group, 2 (13.3%) patients required additional anesthesia.

**DISCUSSION**

For clinical use, mepivacaine and bupivacaine are currently being developed as racemic mixtures of equivalent proportions of the “S” & “R” configuration, whereas ropivacaine is being developed as the refined S-enantiomer (enantiomeric purity - 99.5%). Chemically, ropivacaine is the monohydrate of the hydrochloride salt 1-propyl-2’,6’-piperidoxylide [9]. Ropivacaine has less lipophilic properties and hence has a lower likelihood of penetrating large myelinated motor fibers compared to bupivacaine. As a result, it preferentially acts on the pain-mediating Aδ and C nerves instead of the motor-functioning Aβ fibers [10].

After its commercial release, ropivacaine has been extensively used for perioperative pain relief in the medical field, with consistently better outcomes than other local anesthetic agents [4]. Its use in the dental discipline has expanded to studies on periodontic procedures to evaluate its anesthetic efficacy [11], topical anesthesia of the oral mucosa [12], simple extraction procedures [3,13,14], lower third molar surgeries [1,4,5,15-19], surgical removal of the upper third molars [20], surgical removal of chronic periapical lesions [21], oral aphthosis [22], mandibular osteotomy [23], and postoperative pain control after elective cleft palate repair in children [24].

1. **Onset of anesthesia**

In a study by Keramidas et al. [25], comparing digital block findings after administration of 0.75% ropivacaine versus 2% lignocaine, lignocaine was faster to induce...
Ropivacaine for maxillary third molar removal

anesthesia. The mean onset time for ropivacaine & lignocaine was 4.5 min & 1.3 min, respectively. In bilateral symmetrically impacted mandibular wisdom teeth removal, Budharapu et al. [1] compared 0.5% ropivacaine and 2% lignocaine hydrochloride. The onset of anesthesia for lignocaine and ropivacaine varied from 1 to 2 min and 2 to 3 min, respectively, indicating that 2% lignocaine hydrochloride had the quickest onset of anesthesia. In a similar study by Reddy KV et al. [4] and Bansal V et al. [14], lignocaine was faster to act compared to ropivacaine. In our study, the mean onset of anesthesia was statistically insignificant for the ropivacaine group compared with the lignocaine with adrenaline group.

2. The intensity of pain

Pain intensity was assessed subjectively using the Verbal Rating Scale [8]. In our study, none of the participants from either group experienced any pain throughout the procedure, but they withstood the procedure well with comfort, indicating adequate pain control. These findings are similar to those of other studies, such as Budharapu et al. [1], Bansal et al. [14], Brković et al. [20], and Reddy et al. [4].

3. Need for additional anesthesia

There was no need for additional local anesthetics in the ropivacaine group, while in the lignocaine with adrenaline group, 13.3% of patients required additional anesthesia. The need for supplemental injections can be due to several factors such as the presence or absence of infection, the status of the tooth being removed, anesthetic technique, patient’s anxiety, and pain perception during the procedure.

4. Blood Pressure and Heart Rate

In studies by Reddy et al. [4] and Mishra et al. [11], the perioperative changes in heart rate and blood pressure were insignificant. Bansal et al. [14] noted no statistically significant difference in the mean systolic and diastolic pressure values pre- and postoperatively 45 min after administration of 0.75% ropivacaine and 2% lignocaine with adrenaline, while the mean systolic blood pressure was increased in the ropivacaine and lignocaine groups. Keramidas et al. [25] observed no major difference between 0.75% ropivacaine and 2% lidocaine in the systolic blood pressure index for the digital-brachial artery. The short-term rise in heart rate and blood pressure was apparent in either group at different periods, but there were no significant differences in our study. The addition of a vasoconstrictor to the anesthetic solution slows down the absorption of the local anesthetic solution into the circulation, thus decreasing its systemic toxicity level. However, it transiently increases blood pressure and heart rate [26]. It has been observed that endogenous catecholamines are released in response to stress and pain immediately following administration of the local anesthetic injection, which leads to a short-term increase in heart rate and blood pressure; however, this is not due to the effect of the local anesthetic agent [4]. In our study, both solutions had slight effects on the cardiovascular system perioperatively.

Long-acting local anesthetics have the obvious advantage of delivering long-lasting analgesia, reducing the necessity for analgesic drugs post-surgery [4]. Although the duration of anesthesia was not evaluated in our study, the early postoperative duration of ropivacaine has been studied in the literature [10]. None of the procedures following the onset of anesthesia lasted for more than 30 min in our study.

Based on the findings of this study, we conclude that 0.75% ropivacaine acts as effectively as 2% lignocaine with 1:80000 adrenaline. It matches with the ‘Gold standard’ in terms of the onset of anesthesia, intensity of pain during extraction, need for additional anesthesia, heart rate, and blood pressure changes at different time periods. It may not be prudent to advocate for the superiority of one local anesthetic over the other. However, the use of any of the two anesthetics is satisfactory for its use in the removal of maxillary wisdom teeth. No adverse events were reported in any of the patients with either anesthetic solution. Hence,
0.75% ropivacaine is a safe, adrenaline-free, and hemodynamically stable local anesthetic option for dental practitioners. One of the drawbacks of our study was the small sample size, as our study included only 15 participants. This figure may not accurately reflect the general population. However, the justification for the small sample size was that it was important to conduct a randomized split-mouth case-control study. In addition, the duration of anesthesia was not assessed. Moreover, the authors included maxillary third molar extractions of similar difficulty to avoid bias, although this was not specified as an inclusion criterion. In the future, triple-blinded trials with a larger sample size and an assessment of the duration of anesthesia are recommended.

REFERENCES

1. Budharapu A, Sinha R, Uppada UK, Subramanya Kumar AV. Ropivacaine: a new local anaesthetic agent in maxillofacial surgery. Br J Oral Maxillofac Surg 2015; 53: 451-4.
2. Earnberg M, Kopp S. Ropivacaine for dental anesthesia: a dose-finding study. J Oral Maxillofac Surg 2002; 60: 1004-10.
3. Ranjan R, Santhosh Kumar SN, Singh M. Comparison of efficacy of 0.75% ropivacaine and 2% lidocaine with 1:200,000 adrenaline in pain control in extraction of mandibular posterior teeth: a double-blind study. Indian J Dent Res 2018; 29: 611-5.
4. Reddy KV, Jadhav A, Bholu N, Mishra A, Dakshinkar P. Is 0.75% ropivacaine more efficacious than 2% lignocaine with 1:80,000 epinephrine for IANB in surgical extraction of impacted lower third molar? Oral Maxillofac Surg 2019; 23: 225-31.
5. Bhargava D, Chakravorty N, Rethish E, Deshpande A. Comparative analysis of the anesthetic efficacy of 0.5 and 0.75% ropivacaine for inferior alveolar nerve block in surgical removal of impacted mandibular third molars. J Maxillofac Oral Surg 2014; 13: 431-4.
6. Aliabadi F, Divanpour V, Mardani M. Changes in blood pressure and pulse rate of patients without systemic diseases following the injection of 2% lidocaine plus epinephrine 1:80000 in an inferior alveolar nerve block - a prospective study. Ann Maxillofac Surg 2020; 10: 361-4.
7. Chan AW, Tetzlaff JM, Altman DG, Laupacis A, Gotzsche PC, Krleža-Jerić K, et al. SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med 2013; 158: 200-7.
8. Johnson A, Harikrishnan S, RadhikaDevi B. Comparative Study on the Effectiveness of Granisetron and Metoclopramide for Reducing Propofol Injection Pain. J Med Sci Clin Res 2017; 05: 20750-63.
9. Mcleure JH. Ropivacaine. Br J Anaesth 1996; 76: 300-7.
10. Kuthiala G, Chaudhary G. Ropivacaine: a review of its pharmacology and clinical use. Indian J Anaesth 2011; 55:
Ropivacaine for maxillary third molar removal

11. Mishra A, Lalani Z, Kalakonda B, Krishnan P, Pandey R, Reddy K. Comparative evaluation of hemodynamic, vasoconstrictive, and SpO2 variability during different stages of periodontal surgery performed using 0.5% ropivacaine or 2% lignocaine HCl (1:80,000 adrenaline) local anesthesia: A randomized, double-blind, split-mouth pilot study. J Indian Soc Periodontol 2018; 22: 243-8.

12. Franz-Montan M, Silva AL, Cogo K, Bergamaschi C, Volpato MC, Ranali J, et al. Efficacy of 1% ropivacaine gel for topical anesthesia of human oral mucosa. Quintessence Int 2007; 38: 601-6.

13. Beneti IM, Gulinelli JL, Ponzoni D, Brandini DA, Aranega AM, Garcia Junior IR, et al. Comparative evaluation of cardiovascular effects showed best results of ropivacaine front prilocaine on extractions simple in the jaw. Dent Oral Craniofacial Res 2015; 1: 109-13.

14. Bansal V, Kumar D, Mowar A, Bansal A. Comparison of ropivacaine 0.75 % and lignocaine 2 % with 1:200,000 adrenaline in dental extractions: single blind clinical trial. J Maxillofac Oral Surg 2018; 17: 201-6.

15. Crincoli V, Favia G, Limongelli L, Tempesta A, Brienza N. The effectiveness of ropivacaine and mepivacaine in the postoperative pain after third lower molar surgery. Int J Med Sci 2015; 12: 366-70.

16. Tijanic M, Buric N, Jovanovic G. Evaluation of anesthetic effect of ropivacaine in surgery of chronic periapical lesions. Med Pregl 2010; 63: 366-70.

17. Ghezal H, Bouvet S, Kabani S, Ripart J, Cuivillon P. Ropivacaine versus placebo on postoperative analgesia and chronic pain following third molar extraction: a prospective randomized controlled study. J Stomatol Oral Maxillofac Surg 2020; 121: 113-7.

18. Brković B, Andrić M, Ćalasan D, Milić M, Stepić J, Vučetić M, et al. Efficacy and safety of 1% ropivacaine for postoperative analgesia after lower third molar surgery: a prospective, randomized, double-blinded clinical study. Clin Oral Investig 2017; 21: 779-85.

19. Brković B, Zlatkovic M, Jovanovic D, Stojic D. Maxillary infiltration anesthesia by ropivacaine for upper third molar surgery. Int J Oral Maxillofac Surg 2010; 39: 36-41.

20. Beneti IM, Gulinelli JL, Ponzoni D, Brandini DA, Aranega AM, Garcia Junior IR, et al. Efficacy of 1% ropivacaine for postoperative analgesia after lower third molar surgery: a prospective, randomized, double-blinded clinical study. J Maxillofac Oral Surg 2018; 17: 201-6.

21. Tijanic M, Buric N, Jovanovic G. Evaluation of anesthetic effect of ropivacaine in surgery of chronic periapical lesions. Med Pregl 2010; 63: 366-70.

22. Gasparini G, Saponaro G, Gasparini D, Foresta E, Azzuni C, Adduci A, et al. The use of ropivacaine in therapeutic treatment of oral aphthosis. Biomed Res Int 2018; 2018: 1868254.

23. Chatellier A, Daugé AE, Caufourier C, Maksud B, Cambert JF, Bénaud H. Inferior alveolar nerve block with ropivacaine: effect on nausea and vomiting after mandibular osteotomy. Rev Stomatol Chir Maxillofac 2012; 113: 417-22.

24. Coban YK, Senoglu N, Oksuz H. Effects of preoperative local ropivacaine infiltration on postoperative pain scores in infants and small children undergoing elective cleft palate repair: Statistical considerations to transform interesting hypotheses into significant conclusions. J Craniofac Surg 2009; 19: 1221-4.

25. Keramidas EG, Rodopoulou SG. Ropivacaine versus lidocaine in digital nerve blocks: a prospective study. Plast Reconstr Surg 2007; 119: 2148-52.

26. Oliveira NE, Lima Filho NS, Lima EG, Vasquez EC. Effects of regional anesthesia with ropivacaine on arterial pressure and heart rate in healthy subjects. Eur J Oral Sci 2006; 114: 27-32.